CN118369351A - Dsg2组合物和方法 - Google Patents

Dsg2组合物和方法 Download PDF

Info

Publication number
CN118369351A
CN118369351A CN202280073102.9A CN202280073102A CN118369351A CN 118369351 A CN118369351 A CN 118369351A CN 202280073102 A CN202280073102 A CN 202280073102A CN 118369351 A CN118369351 A CN 118369351A
Authority
CN
China
Prior art keywords
dsg2
seq
protein
region
isolated polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280073102.9A
Other languages
English (en)
Chinese (zh)
Inventor
符施茵
R·E·泰乐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Avada Treatment Co
Original Assignee
Avada Treatment Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avada Treatment Co filed Critical Avada Treatment Co
Publication of CN118369351A publication Critical patent/CN118369351A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN202280073102.9A 2021-11-02 2022-11-02 Dsg2组合物和方法 Pending CN118369351A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163274707P 2021-11-02 2021-11-02
US63/274,707 2021-11-02
PCT/US2022/079106 WO2023081674A1 (en) 2021-11-02 2022-11-02 Dsg2 compositions and methods

Publications (1)

Publication Number Publication Date
CN118369351A true CN118369351A (zh) 2024-07-19

Family

ID=84569745

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280073102.9A Pending CN118369351A (zh) 2021-11-02 2022-11-02 Dsg2组合物和方法

Country Status (12)

Country Link
US (1) US20240279304A1 (https=)
EP (1) EP4426430A1 (https=)
JP (1) JP2024540220A (https=)
KR (1) KR20240110819A (https=)
CN (1) CN118369351A (https=)
AR (1) AR127555A1 (https=)
AU (1) AU2022382972A1 (https=)
CA (1) CA3236070A1 (https=)
IL (1) IL312219A (https=)
MX (1) MX2024005327A (https=)
TW (1) TW202334190A (https=)
WO (1) WO2023081674A1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965197A (en) 1987-06-12 1990-10-23 Massachusetts Institute Of Technology Coryneform expression and secretion system
KR100316347B1 (ko) 1998-09-15 2002-08-27 한미약품(주) 대장균엔테로톡신ⅱ신호펩티드의변형체와인체성장호르몬의융합단백질을발현하는재조합미생물및그를이용한인체성장호르몬의제조방법
DE10057397A1 (de) 2000-11-18 2002-05-23 Hella Kg Hueck & Co Vorrichtung zur Ölstandsmessung
US8093016B2 (en) 2007-05-21 2012-01-10 Danisco Us Inc. Use of an aspartic protease (NS24) signal sequence for heterologous protein expression
US8324578B2 (en) 2008-09-30 2012-12-04 Apple Inc. Hidden sensors in an electronic device
US8975041B2 (en) 2009-09-10 2015-03-10 Biocon Limited Fusion proteins and method of expression thereof
JP2012107935A (ja) * 2010-11-16 2012-06-07 Mitsubishi Chemicals Corp Ｄｅｓｍｏｇｌｅｉｎ−２蛋白質による脳梗塞の検査方法
CN103648489A (zh) 2011-05-11 2014-03-19 儿童医疗中心有限公司 多抗原提呈免疫原性组合物及其方法和用途
US20190353652A1 (en) * 2017-01-13 2019-11-21 The Hospital For Sick Children Method for Diagnosis of Arrhythmogenic Right Ventricular Cardiomyopathy
WO2022132854A1 (en) * 2020-12-15 2022-06-23 Arvada Therapeutics, Inc. Dsg2 compositions and methods for the treatment of covid-19

Also Published As

Publication number Publication date
JP2024540220A (ja) 2024-10-31
AR127555A1 (es) 2024-02-07
IL312219A (en) 2024-06-01
AU2022382972A1 (en) 2024-05-09
TW202334190A (zh) 2023-09-01
CA3236070A1 (en) 2023-05-11
EP4426430A1 (en) 2024-09-11
US20240279304A1 (en) 2024-08-22
MX2024005327A (es) 2024-05-21
WO2023081674A1 (en) 2023-05-11
KR20240110819A (ko) 2024-07-16

Similar Documents

Publication Publication Date Title
ES2847293T3 (es) Regímenes de tratamiento para el tratamiento de enfermedades neurológicas
US20180112193A1 (en) Csf1 therapeutics
KR102833432B1 (ko) 조직 석회화의 치료 방법
JP2022002528A (ja) 組織修復のための二重特異性治療用タンパク質
ES2819866T3 (es) Polipéptido ANGPTL8 y su uso para el tratamiento de condiciones asociadas con triglicéridos elevados
JP6825181B2 (ja) 膵炎を治療するための薬剤の製造におけるｉｌ−２２二量体の使用
EA009938B1 (ru) ЛЕЧЕНИЕ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ С ПРИМЕНЕНИЕМ ИНТЕРФЕРОНА-β
CA3202364A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US20240043495A1 (en) Dsg2 compositions and methods for the treatment of covid-19
US20240279304A1 (en) Dsg2 compositions and methods
JP7824885B2 (ja) 表皮水疱症の治療で使用するためのホーミングペプチド誘導デコリン複合体
US20240173376A1 (en) Trem-1 inhibitors for the treatment of marfan syndrome
RU2446174C2 (ru) Пептид с антипролиферативной активностью и фармацевтическая композиция для лечения пролиферативных заболеваний
JP6416480B2 (ja) 関節リウマチまたはその関連疾患の予防または治療剤
JP2019509731A (ja) 神経損傷を治療するペプチドベースの方法
CN116648255A (zh) 用于治疗covid-19的dsg2组合物和方法
US20220133849A1 (en) Compositions and methods for the treatment of smooth muscle dysfunction
WO2022020544A1 (en) Method of treating an inflammatory condition
KR20260040257A (ko) Hb-egf/egfr 경로 활성화와 관련된 신장 질환치료에서 사용하기 위한 hb-egf 억제제 및 코르티코스테로이드 제제의 조합
HK1223556B (zh) Il-22二聚体在制备用於治疗胰腺炎的药物中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination